[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-suppression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-suppression":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,88,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100495559","mobile-video-directly-observed-therapy-dot-for-immunosuppression-medication-adherence-in-adolescent-heart-transplant-recipients-100495559",false,"NCT05732779","Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients","Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients: Enhancing Technological Innovation and Strengthening the Role of Small Businesses in Meeting Needs of Adolescent Organ Transplant","Inclusion Criteria:\n\n* Eligible participants are 10-21 years of age\n* Have received a heart transplant and are followed participating pediatric heart transplant centers\n* English-speaking or Spanish-speaking\n* Own a smart-phone or have access to the mobile app through other devices\n* Are willing to receive information through it\n* Have a MLVI score of greater than 2.0 over the last year\n\nExclusion Criteria:\n\n• Those with cognitive impairments will not be eligible for enrollment due to inability to provide informed assent","ALL","10 Years","21 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.",[27,28,29,30,31,32,33],"Heart Transplant Rejection","Immune Suppression","Pediatric Heart Transplant","Medication Nonadherence","Health Behavior","Remote Monitoring","Patient Engagement","RECRUITING","2026-02-24",{"date":37,"type":38},"2026-02-27","ACTUAL",{"date":40,"type":38},"2024-10-01",{"date":42,"type":21},"2027-05-01",{"name":44,"class":45},"University of Florida","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100563046","overcoming-immunosuppression-and-rebalancing-the-immune-response-in-ovarian-cancer-study-100563046","NCT06611072","OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study","RENAISSANCE","Inclusion Criteria:\n\n* Subjects should be at least 18 years old and mentally competent;\n* Newly diagnosed patients with OC who go for primary debulking surgery or patients with OC who are scheduled for interval debulking;\n* Controls: women who undergo surgery for benign gynaecological conditions under general anaesthesia.\n\nExclusion Criteria:\n\n* Mentally incompetent;\n* Pregnant or breastfeeding;\n* Known inflammatory of infectious diseases or an immunosuppressive status;\n* Using medication interfering with the immune system;\n* Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas);\n* Serious psychiatric pathology;\n* A self reported alcohol consumption of \\>21 units per week.",true,"FEMALE","18 Years",{"count":57,"type":21},90,[24],"Ovarian cancer (OC) is one of the most lethal cancers in the world due to late-stage disease at diagnosis. Standard therapy consists of debulking surgery and chemotherapy. However, despite this aggressive treatment, recurrent disease almost invariably occurs resulting in a five-year survival rate of approximately 30%.\n\nImmunotherapy could be a way to increase survival in OC patients. However, a major barrier to a successful deployment of cancer immunotherapy for ovarian cancer patients is the immunosuppressive tumor microenvironment.\n\nEnvisioned solution\u002Fresearch direction\n\nTumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator that is involved in the pathogenesis of OC. To improve the patient's outcome and identify novel therapeutic targets, one needs a deeper understanding of the tumor-induced changes in the bone marrow myeloid progenitor cells. Furthermore, treatment of these cells by nanoparticles or other agents that induce a program of 'trained immunity' may be a novel way to re- educate myeloid cells and their bone marrow progenitors in OC patients.\n\nHypothesis\n\nWe hypothesize that by exposing myeloid cells or their progenitors to various agents that induce trained immunity (e.g. trained immunity-inducing agents: BCG, heat-killed Candida,), these immune cells will undergo functional reprogramming to induce a tumor-suppressive phenotype. In the future, this could be explored as a novel immunotherapy for tumors that are refractory to conventional treatment.\n\nObjective\n\nTo characterize and phenotype the immune state of OC patients compared to controls without cancer with a focus on the hematopoietic organs and the immune cells originating from these organs. In addition, the effect of established trained immunity-inducing agents on these cells will be evaluated in vitro, potentially providing new therapies.\n\nThis will be executed by assessing the transcriptional, epigenetic, and functional reprogramming of circulating monocytes and myeloid progenitor cells in OC and by assessing the in vitro effect of trained immunity inducers on the reprogramming of circulating monocytes and myeloid progenitor cells.\n\nStudy design: investigator-initiated, multi-center explorative cross-sectional study at the Catharina hospital Eindhoven, Radboud University Medical Center and Eindhoven University of Technology.",[61,62,63,28,64],"Ovarian Neoplasms","Ovarian Cancer","Ovarian Carcinoma","Immune System Suppression",[66,67,68,69,70,71,72,73,74,75,76,77],"Ovarian cancer","Immune system","Immune suppression","Immune system suppression","Immunotherapy","Monocytes","Myeloid cells","Vena punction","Bone marrow aspiration","Spleen biopsy","Peritoneal fluid","Tumor biopsy","2025-12-05",{"date":80,"type":38},"2025-12-12",{"date":82,"type":38},"2025-01-01",{"date":84,"type":21},"2027-12",{"name":86,"class":45},"Gynaecologisch Oncologisch Centrum Zuid",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":53,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":96,"targetDuration":98,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":110,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":87},"100484735","early-severe-illness-translational-biology-informatics-in-humans-100484735","NCT05591924","Early Severe Illness TrAnslational BioLogy InformaticS in Humans","Prospective Observational Study of Biology of Critical Illness","ESTABLISH","Inclusion Criteria:\n\n* Age ≥18 years old\n* ≤48h since ICU admission\n* ICU admission within 72h of presentation to the emergency department (ER)\n* Clinical critical illness suspected on the basis of any one of the following:\n\n  1. Altered mental status (GCS\\\u003C15)\n  2. Cardiovascular collapse (presence of any: Heart rate \\>90, systolic blood pressure \\\u003C90, presence of vasopressors, lactate \\>2.0)\n  3. Respiratory collapse (presence of any: respiratory rate \\>20, PaCO₂ \\\u003C32 mm Hg, supplemental oxygen, invasive or non-invasive ventilation)\n  4. Suspected severe infection (presence of any: temperature \\>38°C or \\\u003C36°C, white blood cell (WBC) count \\>12,000\u002Fmm³ or \\\u003C4,000\u002Fmm³, presence of 1 or more antibiotics at the time of ICU admission)\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* \\>72h since ICU admission\n* Admission to ICU in patients \\>72h after the presentation to the ER\n* No evidence of critical illness (ICU admission due to bed-spacing)",{"count":97,"type":21},1000,"24 Months","OBSERVATIONAL","Advanced stages of the response to life-threatening infection, severe trauma, or other physiological insults often lead to exhaustion of the homeostatic mechanisms that sustain normal blood pressure and oxygenation. These syndromic presentations often meet the diagnostic criteria of sepsis and\u002For the acute respiratory distress syndrome (ARDS), the two most common syndromes encountered in the intensive care unit (ICU). Although critical illness syndromes, such as sepsis and ARDS, have separate clinical definitions, they often overlap clinically and share several common injury mechanisms. Moreover, there are no specific therapies for critically ill patients, and as a consequence, approximately 1 in 4 patients admitted to the ICU will not survive.\n\nThe purpose of this observational study is to identify early patient biologic factors that are present at the time of ICU admission that will help diagnose critical illness syndromes earlier, identify who could benefit most from specific therapies, and enable the discovery of new treatments for syndromes such as sepsis and ARDS.",[102,103,104,105,106,107,28,108,109],"Sepsis","ARDS","Critical Illness","Neurocognitive Dysfunction","Shock, Septic","Ventilator Associated Pneumonia","Inflammation","SIRS",[111,102,103,108,112,113,114,115],"Critical Care","Immune responses","Neurocognition","Critical illness","Translational Biology","2025-10-01",{"date":118,"type":38},"2025-10-06",{"date":120,"type":38},"2024-04-26",{"date":122,"type":21},"2034-12-31",{"name":124,"class":45},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":87},"100496041","phase-2-nivolumab-combined-with-sox-used-in-the-perioperative-treatment-100496041","NCT05739045","Nivolumab Combined With SOX Used in the Perioperative Treatment","A Multicenter, Prospective, Phase Ⅱ Clinical Study of Nivolumab Combined With SOX in the Perioperative Treatment of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be enrolled in the study:\n\n1\\. Patients voluntarily participate in the study and sign the informed consent form; 2. Age ≥ 18 years and ≤ 75 years; 3. Have pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; 4. Patients with gastric or gastroesophageal junction adenocarcinoma at the clinical staging of cT3-4 or N+, M0 (staging according to AJCC version 8) who could be radically resected as determined by CT and laparoscopy; 5. Have not received anti-tumor therapy (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.); 6. Planned surgical treatment after completion of neoadjuvant therapy; 7. Able to swallow tablets normally; 8. ECOG score 0-1; 9. Expected survival \\>=12 months; 10. Main organ functions normal, i.e., meeting the criteria below:\n\n1. Blood routine examination criteria shall meet:\n\n   (No blood transfusion or blood products within 14 days, no G-CSF or other hematopoietic stimulating factors are used for correction) Absolute neutrophil count ≥1.5×109\u002FL; Platelet ≥80×109\u002FL; Hemoglobin ≥ 80 g\u002FL\n2. Criteria for biochemical tests:\n\nTotal bilirubin \\\u003C1.5×ULN; ALT and AST≤2.5×ULN;\n\nSerum Cr ≤ 1.5 × ULN or endogenous creatinine clearance \\> 50 ml\u002Fmin (males: Endogenous creatinine clearance rate = ((140-age) × body weight)\u002F(72 × serum Cr); female: endogenous creatinine clearance rate = ((140-age) × body weight)\u002F(72 × serum Cr) × 0.85; body weight unit: kg; serum Cr unit: mg\u002FmL):\n\n11\\. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and be willing to use a highly effective method of contraception during the trial and for 120 days after the last dose. Male subjects with partners of childbearing potential should be surgically sterilized or agree to use highly effective methods of contraception during the trial and for 120 days after the last dose;\n\nExclusion Criteria:\n\nPatients with any of the following are not to be enrolled in the study:\n\n1. Patients with unresectable factors, including unresectable tumor causes or unresectable surgical contraindications or refusal of surgery;\n2. Previous or concurrent other malignancy;\n3. Suffering from any chronic or major illness considered intolerable to treatment (eg, severe cardiac disease, uncontrolled hypertension, some degree of hepatic or renal dysfunction, etc.)\n4. Patients who have previous gastrointestinal perforation, abdominal abscess or recent (within 3 months) intestinal obstruction or imaging and clinical symptoms suggestive of intestinal obstruction;\n5. Patients having clinically significant bleeding symptoms or definite bleeding tendency within 3 months before the first dose of study drug, such as gastrointestinal bleeding, hemorrhagic gastric ulcer or suffering from vasculitis; if stool occult blood is positive at baseline, reexamination may be performed; if stool occult blood remains positive after reexamination, gastroscopy is required (except for patients having gastroscopy within 3 months before enrollment to exclude such condition);\n6. Patients in the active stage of infection requiring treatment (such as antibacterial drugs, antiviral drugs, antifungal drugs);\n7. Active hepatitis (hepatitis B reference: HBsAg positive and HBV DNA ≥ 500 IU\u002Fml; hepatitis C reference: HCV antibody positive and HCV viral copy number \\> upper limit of normal);\n8. Patients with congenital or acquired immunodeficiency (such as HIV infection);\n9. Patients with any active autoimmune disease or history of autoimmune disease with potential relapse;\n10. Planned or previous organ or allogeneic bone marrow transplant;\n11. Patients with current interstitial pneumonia or interstitial lung disease, or previous history of interstitial pneumonia or interstitial lung disease requiring steroids, or subjects with active pneumonia or severe lung function impairment on screening CT; active pulmonary tuberculosis;\n12. Ongoing or recent treatment with immunosuppressive drugs or systemic corticosteroids to achieve immunosuppression;\n13. Patients who have received a live attenuated vaccine within 28 days prior to the first dose of study drug or who require administration of such vaccine during treatment or within 60 days after the last dose;\n14. Patients with known hypersensitivity to any of the study drugs or any of their excipients;\n15. Nursing mothers;\n16. Any factors that, in the judgment of the investigator, could affect patient safety and force the termination of the study","80 Years",{"count":134,"type":21},46,[136],"PHASE2","To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;",[28,139],"Gastric Cancer","2024-07-07",{"date":142,"type":38},"2024-07-09",{"date":144,"type":38},"2022-11-03",{"date":146,"type":21},"2024-12-31",{"name":148,"class":45},"Xiangdong Cheng"]